Want to see AMGN full AI Analyst Report?
Operating Expense Breakdown
Details core costs like R&D, marketing, and admin, offering insight into how efficiently Amgen runs and where it’s prioritizing investment.R&D and SG&A have trended higher as Amgen ramps late‑stage programs and commercial launches—management is consciously trading near‑term margin for pipeline and manufacturing scale‑up to offset losses of exclusivity in legacy brands. "Other" is highly lumpy (OI&E, one‑offs and timing items), so quarterly profits will show swingy noise even as revenue and guidance improve. Investors should expect continued elevated investment and episodic charges for growth upside, while monitoring OI&E guidance and the outstanding tax audit risk that could materially shift results.
Date | Research and Development | Selling, General, and Administrative | Other |
|---|---|---|---|
Jun 30, 2026 | $1.87B | $1.75B | $116.00M |
Mar 31, 2026 | $1.72B | $1.60B | -$113.00M |
Dec 31, 2025 | $2.14B | $1.95B | $76.00M |
Sep 30, 2025 | $1.90B | $1.72B | $329.00M |
Jun 30, 2025 | $1.74B | $1.69B | $77.00M |
Mar 31, 2025 | $1.49B | $1.69B | $830.00M |
Dec 31, 2024 | $1.72B | $1.88B | $61.00M |
Sep 30, 2024 | $1.45B | $1.63B | $71.00M |
Jun 30, 2024 | $1.45B | $1.78B | $11.00M |
Mar 31, 2024 | $1.34B | $1.81B | $105.00M |